Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus）
Recruiting
Observational Study
Esophageal Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,500 (estimated)
- Sponsor
- Shu Peng · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This AI-driven model leverages multimodal data-such as radiomics, pathomics, genomics, and broader multi-omics profiles-to capture complementary aspects of tumor biology and predict treatment response and prognosis.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Histopathologically diagnosed esophageal cancer
2. Complete baseline clinical data available (including demographic characteristics, ECOG performance score, TNM staging, etc.)
3. No other primary malignant tumors
4. Provision of informed consent
5. Availability of pre-treatme…
Contacts